Literature DB >> 7732779

SPECT imaging of gliomas with Thallium-201 and Technetium-99m-HMPAO.

H Sjöholm1, D Elmqvist, S Rehncrona, I Rosén, L G Salford.   

Abstract

Sequential Thallium-201 and Technetium-99m-HMPAO SPECT images were obtained from 7 patients with high-grade gliomas and 5 patients with low-grade gliomas. The histo-pathological tumor-type was verified from either biopsy specimens or resected tissue from surgery. There was an intense uptake of Thallium-201 in all high-grade gliomas. Compared to the contralateral hemisphere the mean uptake was 4.6 times higher. Low-grade gliomas showed only a marginally increased Thallium-201 uptake (1.4 times). No overlap existed between the two groups. There was no correlation between Technetium-99m-HMPAO uptake and tumor type. Thallium-201 appears to be a promising radiopharmaceutical for differentiating high- and low-grade gliomas, whereas Technetium-99m-HMPAO is not.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7732779     DOI: 10.1111/j.1600-0404.1995.tb05846.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  4 in total

1.  Neuroradiological assessment of newly diagnosed glioblastoma.

Authors:  Srini Mukundan; Chad Holder; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

2.  Evaluation of malignancy in ring enhancing brain lesions on CT by thallium-201 SPECT.

Authors:  K Källén; M Heiling; A M Andersson; A Brun; S Holtås; E Ryding; I Rosén
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-11       Impact factor: 10.154

3.  201Thallium SPECT and 1H-MRS compared with MRI in chemotherapy monitoring of high-grade malignant astrocytomas.

Authors:  K Kallén; I M Burtscher; S Holtås; E Ryding; I Rosén
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

4.  CT-based quantitative SPECT for the radionuclide ²⁰¹Tl: experimental validation and a standardized uptake value for brain tumour patients.

Authors:  Kathy Willowson; Dale Bailey; Geoff Schembri; Clive Baldock
Journal:  Cancer Imaging       Date:  2012       Impact factor: 3.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.